Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Wino115on Jan 23, 2022 2:16pm
135 Views
Post# 34350163

RE:Questions during the free breakfast

RE:Questions during the free breakfastGreat open ended questions. Let's hope someone asks these and they elaborate.
palinc2000 wrote: 1-When will final determination for Nash be announced? Are there still only 2 options i.e partnering or going alone ?
2-When will you provide guidance on revenues?
3-Can you provide more color on the hiring spree ....as there appears to be a big disconnect between the very subdued commercial activities and  the number of high level management jobs posted
4-Tens and hundreds of millions of funds will be required to fund the R&D  and pay back the Convert....Do  you have a clear shareholder friendly plan ?
5--What can you share with us with regards to Oncology and can you provide a rough timeline for the near term ?


<< Previous
Bullboard Posts
Next >>